GeneDx shareholders re-elect Stueland and Ryan as directors, ratify Ernst & Young

On June 14, 2023, GeneDx Holdings Corp., a Delaware corporation (the “Company”), held its Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Stockholders considered and voted on the matters listed below. The proposals are described in detail in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 28, 2023. There were 25,590,152 shares of the Class A common stock issued and outstanding on May 8, 2023, the record date for the Annual Meeting. The Stockholders voted on the following proposals at the Annual Meeting, each of which was approved. The final voting results from the Annual Meeting are set forth below. (1) Proposal No. 1 — The Class II Director Election Proposal — To elect two Class II directors of the Company, each to serve a three-year term expiring at the Company’s 2026 annual meeting of stockholders and until such director’s successor is duly elected and qualified or until such direct